Regeneron (REGN) Tops Q2 EPS by $1.18, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron Pharma (REGN) PT Raised to $684 at Cowen
August 6, 2020 8:13 AM EDTCowen analyst Yaron Werber raised the price target on Regeneron Pharma (NASDAQ: REGN) to $684.00 (from $584.00) while maintaining a Market Perform rating.
The analyst commented, "Solid Q2 was driven by strong global Dupi and Eylea sales with modest impact of COVID-19. The neutralizing antibody... More
Eli Lilly tests antibody drug to halt COVID-19 spread in U.S. nursing homes
August 3, 2020 9:20 AM EDTBy Michael Erman and Carl O'Donnell
(Reuters) - Eli Lilly and Co (NYSE: LLY) said on Monday it started a late-stage trial testing whether one of its experimental COVID-19 antibody treatments can prevent the spread of infections in residents and staff at U.S. nursing homes.
The Indianapolis-based drugmaker said it dosed the first participant in the placebo-controlled trial at a nursing home in Illinois.
LY-CoV555, which is being developed in partnership with Canadian biotech AbCellera, is already being studied as a treatment in patients who have contracted the disease. The nursing home... More
Next big COVID-19 treatment may be manufactured antibodies
August 3, 2020 7:13 AM EDTBy Deena Beasley
(Reuters) - As the world awaits a COVID-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders - antibodies designed specifically to attack this new virus.
Development of monoclonal antibodies to target the virus has been endorsed by leading scientists. Anthony Fauci, the top U.S.... More
Rival drugmakers launch joint trial of medicines for COVID-19
August 3, 2020 6:14 AM EDTBy Deena Beasley
(Reuters) - Rival drugmakers AbbVie Inc (NYSE: ABBV), Amgen Inc (NASDAQ: AMGN) and Takeda Pharmaceuticals Inc on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus.
The COVID-19 pandemic is an "all hands on deck moment," David Reese, Amgen's research and development chief told Reuters. "We wanted a trial to be able to quickly sift through multiple agents and prioritize."
... More